50 related articles for article (PubMed ID: 38685671)
1. Dihydroartemisinin-driven selective anti-lung cancer proliferation by binding to EGFR and inhibition of NRAS signaling pathway-induced DNA damage.
Li LG; Peng XC; Yang ZY; Han N; Gou CL; Shi J; Yu LL; Chen NN; Yu TT; Li TF; Li XY; Hu J
Sci Rep; 2024 May; 14(1):11704. PubMed ID: 38778121
[TBL] [Abstract][Full Text] [Related]
2. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
3. Decoding dynamic interactions between EGFR-TKD and DAC through computational and experimental approaches: A novel breakthrough in lung melanoma treatment.
Meher RK; Mir SA; Singh K; Mukerjee N; Nayak B; Kumer A; Zughaibi TA; Khan MS; Tabrez S
J Cell Mol Med; 2024 May; 28(9):e18263. PubMed ID: 38685671
[TBL] [Abstract][Full Text] [Related]
4. Identification of tripeptides against tyrosine kinase domain of EGFR for lung cancer cell inhibition by in silico and in vitro studies.
Kiriwan D; Seetaha S; Jiwacharoenchai N; Tabtimmai L; Sousa SF; Songtawee N; Choowongkomon K
Chem Biol Drug Des; 2022 Mar; 99(3):456-469. PubMed ID: 34923743
[TBL] [Abstract][Full Text] [Related]
5. Click ferrocenyl-erlotinib conjugates active against erlotinib-resistant non-small cell lung cancer cells in vitro.
Biegański P; Godel M; Riganti C; Kawano DF; Kopecka J; Kowalski K
Bioorg Chem; 2022 Feb; 119():105514. PubMed ID: 34864281
[TBL] [Abstract][Full Text] [Related]
6.
Meher RK; Mir SA; Anisetti SS
J Biomol Struct Dyn; 2024 May; 42(8):4169-4184. PubMed ID: 37272907
[TBL] [Abstract][Full Text] [Related]
7. Scalable Production and In Vitro Efficacy of Inhaled Erlotinib Nanoemulsion for Enhanced Efficacy in Non-Small Cell Lung Cancer (NSCLC).
Chauhan G; Wang X; Yousry C; Gupta V
Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986858
[TBL] [Abstract][Full Text] [Related]
8. Identification of potent EGFR-TKD inhibitors from NPACT database through combined computational approaches.
Mir SA; Muhammad A; Padhiary A; Ekka NJ; Baitharu I; Naik PK; Nayak B
J Biomol Struct Dyn; 2023; 41(21):12063-12076. PubMed ID: 36695102
[TBL] [Abstract][Full Text] [Related]
9. Structural insights into conformational stability and binding of thiazolo-[2,3-b] quinazolinone derivatives with EGFR-TKD and
Ahmad Mir S; Paramita Mohanta P; Kumar Meher R; Baitharu I; Kumar Raval M; Kumar Behera A; Nayak B
Saudi J Biol Sci; 2022 Dec; 29(12):103478. PubMed ID: 36389208
[TBL] [Abstract][Full Text] [Related]
10. In Silico and In Vitro Evaluations of Fluorophoric Thiazolo-[2,3-b]quinazolinones as Anti-cancer Agents Targeting EGFR-TKD.
Mir SA; Dash GC; Meher RK; Mohanta PP; Chopdar KS; Mohapatra PK; Baitharu I; Behera AK; Raval MK; Nayak B
Appl Biochem Biotechnol; 2022 Oct; 194(10):4292-4318. PubMed ID: 35366187
[TBL] [Abstract][Full Text] [Related]
11. Development of 1,3-diynyl derivatives of noscapine as potent tubulin binding anticancer agents for the management of breast cancer.
Meher RK; Pragyandipta P; Reddy PK; Pedaparti R; Kantevari S; Naik PK
J Biomol Struct Dyn; 2022; 40(23):13136-13153. PubMed ID: 34583618
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
